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Background: Downstaging and pathologic complete response (pCR) after chemoradiotherapy (CRT) 
may improve progression-free survival and overall survival (OS) after curative therapy of locally advanced 
adenocarcinoma of rectum. The purpose of this study is to evaluate the pathologic response subsequent 
to neoadjuvant chemoradiation in locally advanced rectal adenocarcinoma and any impact of response on 
oncological outcome [disease-free survival (DFS), OS].
Methods: A total of 127 patients with histologically-proven rectal adenocarcinoma, locally advanced, 
were treated with preoperative radiotherapy and concurrent 5-fluorouracil (5 FU), and followed by curative 
surgery. Pathologic response to neoadjuvant treatment was evaluated by comparing pathologic TN (tumour 
and nodal) staging (yp) with pre-treatment clinical staging. DFS and OS were compared in patients with: 
pCR, partial pathologic response and no response to neoadjuvant therapy.
Results:  14.96% (19 patients) had a pCR, 58.27% [74] showed downstaging and 26.77% [34] had no change 
in staging. At follow-up (range, 4–9 years, median 6 years 2 months or 74 months), 17.32% [22] showed 
recurrence: 15.74% [20] distant metastasis, 1.57% [2] pelvic failure. 10.5% [2] of the patients with pCR 
showed distant metastasis, none showed local recurrence. In the downstaged group, nine developed distant 
failure and two had local recurrence (14.86%). Distant failure was seen in 26.47% [9] of those with no 
response to neoadjuvant treatment. DFS and OS rates for all groups were 82.67% and 88.97% respectively. 
Patients with pCR showed 89.47% DFS and 94.7% OS. In partial responders, DFS was 85.1% and OS 
was 90.5%. In non-responders, DFS and OS were 73.5% and 82.3% respectively. Patients with pCR had 
a significantly greater probability of DFS and OS than non-responders. Rectal cancer-related death was 
11.02% [14]: one patient (5.26%) with pCR, 9.47% [7] in the downstaged group and 17.64% [6] of non-
responders.
Conclusions: The majority of patients showed some response to neoadjuvant treatment. Findings of this 
study indicate tumour response to neoadjuvant CRT improves the long-term outcome, with a better result in 
patients with pCR.
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Introduction
Preoperative chemoradiotherapy (CRT) results in local 
control improvement and downstaging with, subsequently, 
the increased possibility of sphincter sparing in low rectal 
tumour and less toxicity in comparison with postoperative 
chemoradiation (1,2). Pathologic downstaging of a rectal 
cancer occurs when the final pathologic stage response is 
less than the preoperative stage of the tumour. A pathologic 
complete response (pCR) (absence of cancer cells in the 
resected surgical specimen) can occur after neoadjuvant 
treatment and this result may confer a survival advantage 
[overall survival (OS) and disease-free survival (DFS)] (3-12).
The aim of the current study is to assess the pathologic 
response rates following neoadjuvant CRT and evaluate 
the influence of response to neoadjuvant treatment on the 
long-term outcome in patients with locally advanced rectal 
cancer.
Methods
Patients
A total of 127 patients with locally advanced (clinical T3, 
T4 or node positive), biopsy proven adenocarcinoma of the 
rectum were involved in this retrospective review, with the 
mean age of 62.1 years (SD: 11.1 years) (ages ranged from 
27–83 years). 33.85% (43 patients) were female and 66.15% 
(84 patients) male.
Pre-treatment staging was performed by endorectal 
ultrasound (ERUS) or magnetic resonance imaging (MRI), 
in addition to a range of other investigations including 
computed tomography (CT) of chest and abdomen, 
colonoscopy, complete blood count, blood chemistry and 
carcinoembriogenic antigen (CEA). All patients were 
treated at The Alfred Hospital, Melbourne, Australia, 
between 2005 and 2010.
Institutional review board approval was granted for this 
study.
Treatment
After signing informed consent forms, all patients received 
neoadjuvant radiotherapy, concurrent with 5-fluorouracil 
(5 FU), at the William Buckland Radiotherapy Centre 
(WBRC) at The Alfred Hospital. Patients received either 
45 or 50.4 Gray (Gy) radiotherapy, 1.8 Gy per fraction, 
one fraction per day, and were treated 5 days per week. 
Treatment was delivered using a 3-field 18/6 MV photon 
technique on a lineal accelerator. The clinical target volume 
included the primary tumour and regional lymph nodes 
(mesorectal, presacral, internal iliac, obturator). All patients 
received either bolus or continue infusion 5 FU.
After radical surgery, all patients received adjuvant 
chemotherapy with weekly 379 mg per square meter 5 FU 
for 20 weeks.
Follow-up
Pathologic response was assessed by comparing postoperative 
pathologic staging (yp) with preoperative clinical staging and 
grouped as pathologic complete responders (pCR), partial 
responders (decrease in tumour or nodal staging) and non-
responders.
During a median follow-up of 74 months, patients 
were clinically evaluated (history and examination) and 
were referred for radiological assessment (chest X-ray, 
abdominal-pelvic CT scan, colonoscopy and other 
investigations) as per clinical indications. 
DFS was defined as the time between surgery and first 
recurrence (local or distant). Cancer specific survival was 
defined as the time between surgery and the time that 
cancer-related death occurred.
Statistical methods
Continuous data were expressed as mean (SD), median and 
the range between parentheses.
Qualitative data are presented as absolute numbers or 
percentages. Comparative analysis of the quantitative data 
was performed using the Student’s t-test. The chi-square or 
Fisher’s exact tests were used for comparing proportions as 
appropriate. Odds ratio (OR) and 95% confidence interval 
(CI) were reported for significant associations. Estimates 
of DFS and OS were calculated using the Kaplan-Meier 
method. Patient and disease factors were evaluated using 
log-ranked test, with result reported as median and 95% CI. 
Statistical significance was defined as P≤0.05.
Results
Patients and tumour characteristics
A total of 127 patients were involved in this study with the 
mean age of 62.1 years (SD: 11.1 years) (range, 27–83 years), 
33.85% (43 patients) were female and 66.15% (84 patients) 
were male.
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Fifty percent of the patients were staged by ERUS, 
48.4% by MRI and 1.6% had both modalities for staging.
Patients and tumour characteristics are listed in Table 1.
Pathologic response
pCR was seen in 14.96% (19 patients) of participants. 
58.26% (74 patients) of patients displayed partial response 
and TN staging did not change in 26.77% (34 patients). 
There was no significant association between patients and 
tumour characteristics and response to treatment (Table 2).
Treatment outcome
After a median follow-up of 74 months, 22 patients (17.32%) 
showed recurrence, including local and distant failure. 
Twenty patients developed distant metastases: six cases 
with liver metastases, six patients developed pulmonary 
metastases, one recurred in bone, two had pelvic recurrence 
and seven patients had metastases in more than one site 
(Table 3).
DFS and cancer-related survival were 82.67% and 
88.97% respectively. DFS curve according to pathologic 
response is shown in Figure 1. OS curve according to 
pathologic response is shown in Figure 2.
Discussion
Neoadjuvant CRT before curative surgery is a widely adopted 
Table 1 Patients and tumour characteristics
Patients and tumour characteristics No. (%)
Female/male ratio 43/85; (33.5% F; 66.4% M)
Mean age [range] 62 [27–83]
Female 60
Male 63
Pre-treatment staging modality
MRI 62 (48.4)
US 64 (50.0)
Both 2 (1.6)
cT stage
cT2 4 (3.12)
cT3 114 (89.0) 
cT4 10 (7.8)
cN stage
cN0 44 (34.3)
cN1 69 (53.9)
cN2 14 (10.9)
cNx 1 (0.7)
MRI, magnetic resonance imaging; US, ultrasound.
Table 2 Patients and tumour characteristics and response to 
treatment
Patients & tumour 
characteristics
Non-responders 
(34 patients) 
Responders  
(93 patients)
P value
Age (SD); [range] 62.4 (12.1); 
[27–83]
61.6 (7.8); 
[44–83]
0.72
Gender (male/female) 59/34 25/9 0.20
Pre-operative T stage 
(%)
0.38
T2 2 (2.2) 1 (2.9)
T3 81 (87.1) 32 (94.1)
T4 10 (10.8) 1 (2.9)
Pre-operative N stage 
(%)
0.55
N0 31 (33.3) 14 (42.4)
N1 52 (55.9) 17 (51.5)
N2 10 (10.8) 2 (6.1)
Table 3 Site and number of recurrence
Site of recurrence Number of patients
Bone 1 no responder
Lung 1 no responder; 5 partial responders
Liver 3 no responders; 2 partial responders; 1 pCR
Lung, liver 1 no responder; 1 partial responder; 1 pCR
Lung, brain 1 no responder
Lung, bone 1 no responder
Lung, peritoneum 1 partial responder
Lung, mediastinum 1 no responder
Pelvis 1 partial responder
Pelvis 1 partial responder
pCR, pathologic complete response. 
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treatment method in locally advanced adenocarcinoma of 
rectum, especially in low and fixed rectal tumour, to improve 
resectability, tumour control and preserve anal sphincter. 
Pathologic response to neoadjuvant treatment in locally 
advanced rectal adenocarcinoma may predict a survival 
advantage (DFS and OS) (2,3,5-7,13,14). pCR rates 
following preoperative CRT are shown in a body of research 
literature to range from 9% to 30% (1,2,7,8,10,11,15,16) 
while some studies report a partial response to neoadjuvant 
treatment of 51% (6,11). The correlation between response 
to neoadjuvant treatment and oncologic outcome has been 
reported in other studies (3,4,6-12,17-23). 
To our knowledge, the data presented in this study is one 
of the largest single-institution reports in the Australian 
literature looking at response rates and long-term outcomes 
of patients with locally advanced, rectal adenocarcinoma.
In our study, 58.26% of the patients showed some 
response to preoperative treatment. pCR was found in 
14.96% of patients, which is comparable to European 
studies which reported rates of 11–16% (1,2,16). None 
of our patients with complete response to neoadjuvant 
treatment showed local recurrence. A lower rate of distant 
failure was observed in the pCR group compared with the 
other two groups and partial responders had less recurrence 
than non-responders.
DFS and OS in the pCR group were 89.47% and 94.7% 
respectively.
In partial responders, DFS and OS were 85.1% and 
90.5% and in non-responders were 73.5% and 82.3% 
respectively. Table 4 demonstrates recurrence and cancer-
related death of the three groups of responders.
Conclusions
This study revealed that preoperative chemoradiation for 
locally advanced adenocarcinoma of the rectum resulted in a 
pathologic response of the primary tumour and lymph nodes 
Table 4 Recurrence and cancer-related deaths by responder groups
Treatment 
outcome
Responders 
[92]
Non-responders 
[34]
P value
Complete 
responder [19]
Partial 
responders [74]
P value
Complete 
responders [19]
Non-responders 
[34]
P value
Recurrence 13 (14.1%) 9 (26.5%) 0.79 2 (10.5%) 11 (14.9%) 0.69 2 (10.5%) 9 (26.5%) 0.26
Cancer-related 
death
8 (8.7%) 6 (17.7%) 0.08 1 (5.3%) 7 (9.5%) 0.59 1 (5.3%) 6 (17.7%) 0.25
Figure 1 Kaplan-Meier curves for disease-free survival (DFS).
Figure 2 Kaplan-Meier curves for overall survival (OS).
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in the majority of patients studied. Our results indicate pCR 
is achievable in a proportion of patients and that response 
to pre-operative CRT can be used as a predictor of tumour 
recurrence rate and long-term outcome.
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